JENKINS DAVID A 4

What Happened

• David A. Jenkins, Chairman of the Board and CEO of Catheter Precision, acquired Series J Preferred Stock on February 12, 2026. The filing reports two acquisitions: 2,491.293 shares and 6,998.195 shares, for a total of 9,489.488 Series J preferred shares.
• These shares were issued in exchange for cancelling an accrued royalty amount and terminating a royalty right under a Series J Exchange Agreement (see the company’s Form 8-K of Feb 12, 2026). No exercise price or dollar value is reported on the Form 4.

Key Details

• Transaction date: February 12, 2026. Form 4 filed: February 18, 2026 (filed 6 days after the transactions; this appears later than the SEC’s usual 2-business-day Form 4 deadline).
• Securities acquired: Series J Preferred Stock (derivative). Reported amounts: 2,491.293 and 6,998.195 shares (total 9,489.488). No price or cash consideration is shown on the Form 4.
• Shares owned after transaction: not disclosed in the Form 4.
• Notable footnotes:
  • The Series J Exchange Agreement cancelled accrued royalties in exchange for Series J Preferred Stock (see Form 8-K).
  • Series J Preferred Stock is not exercisable until stockholder approval is obtained.
  • Series J Preferred Stock has no expiration date.
  • The consideration and price paid for the Series J Preferred Stock are described in the Form 8-K.
  • The filing notes Mr. Jenkins is managing member of SeaCap Management LLC, general partner of FatBoy Capital LP (indicating his relationship to the reporting entity).

Context

• These were not open‑market purchases of common stock but an issuance of preferred shares in a corporate exchange (royalty cancellation for preferred stock). Because the Series J Preferred Stock is not exercisable until shareholder approval, it does not immediately convert into common shares or directly increase the common share float.
• For retail investors: this is a management/financing-related transaction rather than a routine buy/sell of common stock; it’s factual to note the acquisition, but it should not be treated the same way as an open‑market insider purchase of common shares.